US 2025/0026825 A2Published application

Anti-nectin-4 antibody, conjugate including the same, and application thereof

AssigneeSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

InventorsCheng WANG, Dengnian LIU, Fen LI, Liang XIAO, Tongtong XUE, Junyou GE, Jingyi WANG, Le LIU, Qi REN

Life of this patent

Estimating the term…

Abstract

Provided are an anti-Nectin-4 antibody or antigen-binding fragment thereof, an antibody conjugate comprising the same, and use thereof in the manufacture of a medicament, particularly in the manufacture of a medicament for treating and/or preventing cancer.

Claims35

Dependent claims

An antibody or antigen-binding fragment thereof that specifically binds to Nectin-4, comprising:

(1a)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
3,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
4,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
5;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
6,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
7,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
8;
or
(1b)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
9,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
10,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
5;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
6,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
7,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
8;
or
(1c)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
11,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
12 or 63,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
5;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
6,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
7,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
8;
or
(1d)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
13,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
14,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
15;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
16,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
17,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
8;
or
(2a)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
21 or 18,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
22,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
23;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
24,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
25,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
26;
or
(2b)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
27 or 36,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
28,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
23;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
24,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
25,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
26;
or
(2c)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
29 or 44,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
30,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
23;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
24,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
25,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
26;
or
(2d)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
31 or 54,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
32,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
33;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
34,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
35,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
26;
or
(3a)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
39,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
40,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
41;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
42,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
43,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
8;
or
(3b)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
45,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
46,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
41;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
42,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
43,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
8;
or
(3c)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in NO:
47,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
48 or 64,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
41;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
42,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
43,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
8;
or
(3d)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
49,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
50,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
51;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
52,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
53,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
8.

200 more elements

Dependencies are inferred from the claim text.

Facts

Application: 18/026,576Filed 9 Sep 2021
Priority: CN 202010972365.616 Sep 2020
Published: 23 Jan 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification14 codes

C07K 16/2803
Against receptors, cell surface antigens or cell surface determinants: against the immunoglobulin superfamily
A61K 39/00
Medicinal preparations containing antigens or antibodies
A61K 47/68031
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates: the drug being an auristatin
A61K 47/68037
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates: the drug being a camptothecin [CPT] or derivatives

Family

US 12,753,230 B2Related patent
US 2024/0228612 A1Published application
US 2025/0223352 A2Published application
US 2025/0026825 A2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

An antibody or antigen-binding fragment thereof that specifically binds to Nectin-4, comprising:

(1a)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
3,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
4,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
5;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
6,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
7,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
8;
or
(1b)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
9,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
10,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
5;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
6,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
7,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
8;
or
(1c)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
11,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
12 or 63,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
5;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
6,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
7,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
8;
or
(1d)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
13,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
14,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
15;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
16,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
17,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
8;
or
(2a)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
21 or 18,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
22,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
23;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
24,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
25,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
26;
or
(2b)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
27 or 36,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
28,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
23;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
24,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
25,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
26;
or
(2c)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
29 or 44,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
30,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
23;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
24,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
25,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
26;
or
(2d)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
31 or 54,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
32,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
33;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
34,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
35,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
26;
or
(3a)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
39,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
40,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
41;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
42,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
43,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
8;
or
(3b)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
45,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
46,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
41;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
42,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
43,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
8;
or
(3c)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in NO:
47,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
48 or 64,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
41;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
42,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
43,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
8;
or
(3d)
the following three heavy chain CDRs:
CDR-H1 comprising the sequence as set forth in SEQ ID NO:
49,
CDR-H2 comprising the sequence as set forth in SEQ ID NO:
50,
CDR-H3 comprising the sequence as set forth in SEQ ID NO:
51;
and
the following three light chain CDRs:
CDR-L1 comprising the sequence as set forth in SEQ ID NO:
52,
CDR-L2 comprising the sequence as set forth in SEQ ID NO:
53,
CDR-L3 comprising the sequence as set forth in SEQ ID NO:
8.

200 more elements

Facts

Application

18/026,576Filed 9 Sep 2021

Priority

CN 202010972365.616 Sep 2020

Published

23 Jan 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification14 codes

C07K 16/2803
Against receptors, cell surface antigens or cell surface determinants: against the immunoglobulin superfamily
A61K 39/00
Medicinal preparations containing antigens or antibodies
A61K 47/68031
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates: the drug being an auristatin
A61K 47/68037
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates: the drug being a camptothecin [CPT] or derivatives